Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q4 FY26 Earnings Presentation
19 slides from Gland Pharma's earnings presentation, May 15, 2026
Slide 1: Cover letter to stock exchanges
GLAND PHARMA LIMITED May 15, May 2026 15,2026 BSE Limited BSE Limited National National Stock Stock Exchange Exchange of of India India Limited Limited Corporate Relationship Corporate Relationship Department Department Listing Department Listing Department Phiroze Jeejeebhoy Phiroze Jeejeebhoy Towe
Slide 2: Investor Presentation Q4 FY26 & FY26
GLANDI GLAND PHARMA Investor Presentation Presentation Q4 FY26 Q4 FY26 & FY26 & FY26 15 15 th th May May 2026 2026
Slide 3: Safe Harbour Statement
Safe Safe Harbour Harbour Statement Statement The The Presentation Presentation is is to to provide provide the the general general background background information information about about the the Company’s activities Company’s activities as as at at the the date date of of the the Presentation. Pr
Slide 4: Financial Highlights
GLAND Financial Highlights Financial Highlights
Slide 5: Consolidated P&L Highlights
Consolidated Consolidated P&L P&L Highlights Highlights ₹ Mn ?Mn Particulars Particulars Q4 Q4 FY26 FY26 Q4 Q4 FY25 FY25 YoY YoY Q3 Q3 FY26 FY26 QoQ QoQ FY26 FY26 FY25 FY25 YoY YoY Revenue Revenue from from operations operations 17,428 17,428 14,249 14,249 22% 22% 16,954 16,954 3% 3% 64,307 64,307 5
Slide 6: Consolidated Financial Highlights
Consolidated Consolidated Financial Financial Highlights Highlights Revenue Revenue from from Operations Operations Gross Gross Profit 1 ) / Gross Profit*(1) Gross Profit Profit Margin 2 Margin*(2) ) (₹ Mn) (< Mn) (₹ Mn / %) (< 64,307 64,307 56,165 56,165 41,877 41,877 35,261 35,261 65% 63% 14,249 1
Slide 7: Base Business (Gland) P&L Highlights
Base Base Business (Gland) P&L Business (Gland) P&L Highlights Highlights ?Mn ₹ Mn Particulars Q4 FY26 Q4 FY25 YoY Q3 FY26 QoQ FY26 FY25 YoY Revenue from operations 12,648 10,332 22% 11,790 7% 45,613 41,248 11% Other Income 1,072 436 146% 631 70% 3,120 2,079 50% Total Income Total Income 13,720 13,7
Slide 8: Base Business (Gland) Financial Highlights
Base Base Business (Gland) Financial Business (Gland) Financial Highlights Highlights Revenue R e v e n u e from from Operations Operations Gross Gross Profit *1> // Gross Profit (1) Gross Profit Profit Margin 2 Margin*(2)) (₹ (? Mn) Mn) (₹ Mn / %) 27,662 27,662 45,613 45,613 41,248 41,248 23,943 23
Slide 9: Group Financial Highlights (1/2)
Group Group Financial Financial Highlights Highlights (1/2) (1/2) (1) Net Worth Net Worth (1) ROCE (2) //RONW ROCE RONW(3) (₹ Mn) (? (%) (%) —A— RoCE — RoNW 87,238 91,507 1,03,580 11% 15.0% 12% 9% 10.0% 9% 11% 8% 5.0% 0.0% FY24 FY25 FY26 FY24 FY25 FY26 Capital Capital Expenditure Expenditure Asset A
Slide 10: Group Financial Highlights (2/2)
Group Group Financial Financial Highlights Highlights (2/2) (2/2) * Cash Cash and and Bank Bank Balances Balances // Net Net Cash (1) Cash (1) Cash Cash Flow from Operations Flow from Operations (₹ Mn) ■■Total Total Cash (₹ (? Mn) (? Net Cash 9,968 10,314 9,147 33,591 33>591 31,157 31,157 25,562 25
Slide 11: Business Update
GLAND Business Update Business Update
Slide 12: Base Business (Gland) Updates
Base Base Business Business (Gland) (Gland) Updates Updates • •; • • R&D Expenses: Total R&D expenses were ₹506 506 million in Q4 FY26, representing 4% of base business revenue. The R&D expenditure was was mainly mainly focused focused on on complex complex product development and product developmen
Slide 13: Cenexi Updates
Cenexi Cenexi Updates Updates Q4 FY26 Q4 FY26 Q4 FY25 Q4 FY25 Q3 Q3 FY26 FY26 FY26 FY26 FY25 FY25 Particulars Particulars YoY YoY QoQ QoQ YoY YoY € € Mn. Mn. ₹ Mn. ? Mn. € € Mn. Mn. ₹ Mn. ? Mn. € € Mn. Mn. ₹ Mn. ? Mn. € € Mn. Mn. ₹ Mn. ?Mn. € € Mn. Mn. ₹ Mn. ? Mn. Revenue Revenue from from operation
Slide 14: Geographical Revenue
GLAND Geographical Geographical Revenue
Slide 15: US Market
US US Market Market t₹MMn n Group Revenue Contribution Gland Gland Cenexi 24% 24% YoY YoYi 13% 13% YoY YoY 26% 26% YoY YoY i 11% 11% YoY YoY -55% -55% YoY YoY 66% 66% YoY YoY 34,214 33,181 30,387 30,387 34,214 29,766 29,766 33,181 1,033 i ,ud3 621 7,918 7,918 8,685 8,685 9,807 9,807 7,714 7,714 8,29
Slide 16: Europe Market
Europe Europe Market Market ?₹ Mn Mn Group Revenue Contribution Gland Gland Cenexi 36% YoY 34% YoY 15% YoY 21% YoY 40% YoY 36% YoY 14,035 1,883 1,555 12,152 10,470 8,915 4,071 3,814 593 462 3,478 3,352 2,801 402 2,399 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY2
Slide 17: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, (Canada, Australia Australia and and New Zealand) New Zealand) t₹MMn n Group Revenue Contribution Gland Cenexi -2% YoY 12% YoY -24% YoY -1% YoY 56% YoY 40% YoY 2,269 1,374 1,366 903 2,021 II 647 ■ 601 588 437 332 256 454 288 164 166 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY
Slide 18: Rest of the World
Rest of the Rest of the World World t₹MMn n Group Revenue Contribution Gland Gland Cenexi Cenex! 6% YoY 3% YoY 17% YoY ! 7% YoY -6% YoY -3% YoY Own Products ■ TT&CMO TT & CMO 6,066 6,511 4,734 4,606 10,800 11,117 11,117 1,047 11 H 1,145 M 4 5 ™ 1 ’0 4 7 1,254 1,876 1,468 2,404 3,000 2,549 4,921 5,46
Slide 19: Thank You
iGiANPl GLAND PHARMA Thank You Thank You Corporate Office Investor Relations: Gland Gland Pharma Pharma Limited Limited Sampath Sampath Kumar Kumar Pallerlamudi Pallerlamudi Plot Plot No. No. 11 11 & & 84, 84, TSIIC TSIIC Phase: Phase: IV IV Company Company Secretary Secretary & & Compliance Complia